Significant progress has been made in understanding pharmacokinetics (PK),
pharmacodynamics (PD), as well as toxicity profiles of therapeutic proteins in animals and …

Target‐mediated drug disposition (TMDD) is the phenomenon in which a drug binds with
high affinity to its pharmacological target site (such as a receptor) to such an extent that this …

Proteochemometric (PCM) modelling is a computational method to model the bioactivity of
multiple ligands against multiple related protein targets simultaneously. Hence it has been …

Abstract Background and Objectives Prediction of human pharmacokinetics for monoclonal
antibodies (mAbs) plays an important role for first-in-human (FIH) dose selection. This …

Conjugating a hydrophilic and protein-resistant polymer to a protein is a widely used
strategy to extend the in vivo half-life of the protein; however, the benefit of the half-life …

Introduction: The number of monoclonal antibodies available for clinical use and under
development has dramatically increased in the last 10 years. Understanding their …

Subcutaneous injection is an important route of administration for therapeutic proteins that
provides several advantages over other modes of parenteral delivery. Despite extensive …

Currently, more than 350 monoclonal antibodies (mAbs) and mAb derivatives are under
development as therapeutics. The prediction of mAb pharmacokinetics (PK) …

Technology in bioanalysis,-omics, and computation have evolved over the past half century
to allow for comprehensive assessments of the molecular to whole body pharmacology of …

Human clearance prediction for small-and macro-molecule drugs was evaluated and
compared using various scaling methods and statistical analysis. Human clearance is …